- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04167319
A Feasibility Study Investigating Chemotherapy-induced Neuropathy Using Multi-frequency Tactilometry and Patient-reported Outcomes (PRO) (CINCAN-1)
Chemotherapy induced peripheral neuropathy (CIPN) is among the most feared side effects to cancer treatment. The development of CIPN can lead to discontinuation or omission of antineoplastic drugs, possibly affecting efficacy of cancer treatment. There is a lack of knowledge about the natural course of CIPN and to this date, there are no available methods for the early detection of CIPN. With no effective prevention or treatment options, the condition has severe impact on patient quality of life and healthcare expenditure.
This study will investigate the natural course of paclitaxel- and oxaliplatin induced peripheral neuropathy using novel diagnostic techniques. Multi-frequency vibrational technology has provided an objective method for the early detection of diabetic neuropathy. Our study will test the feasibility of this method within the field of clinical oncology and CIPN.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Roskilde, Dinamarca, 4000
- Department of Clinical Oncology and Palliative Care
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- ≥ 18 years of age
- A diagnosis of cancer.
- Fulfil the criteria for starting chemotherapy.
- Scheduled to undergo at least 4 courses of paclitaxel- or oxaliplatin-based chemotherapy.
- No prior paclitaxel, oxaliplatin or other neurotoxic chemotherapy.
Exclusion Criteria:
- Unable to complete PRO measures.
- Previous neurotoxic chemotherapy.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
---|---|
Paclitaxel
Patients scheduled to receive paclitaxel as part of their standard treatment
|
We will observe the natural course of CIPN using multiple measurements
|
Oxaliplatin
Patients scheduled to receive oxaliplatin as part of their standard treatment
|
We will observe the natural course of CIPN using multiple measurements
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Difference in VPT from baseline to 6 mo.
Periodo de tiempo: through study completion, an average of 1 year and 6 months
|
For patients receiving paclitaxel: Difference in vibrograms from baseline compared to vibrograms after the end of the 6th course of chemotherapy or the last course of chemotherapy (if before course no. 6).
|
through study completion, an average of 1 year and 6 months
|
Difference in VPT from Baseline to 4 mo.
Periodo de tiempo: through study completion, an average of 1 year and 6 months
|
For patients receiving oxaliplatin: Difference in vibrograms from baseline compared to vibrograms after the end of the 4th course of chemotherapy or the last course of chemotherapy (if before course no.
4).
|
through study completion, an average of 1 year and 6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Difference in PRO from baseline and during 1. course chemotherapy.
Periodo de tiempo: up to 5 days
|
Difference in the NCCTG-CIPN Questionnaire from baseline compared to 4 days after initiation of chemotherapy course no. 1.
|
up to 5 days
|
Difference in VPT from baseline and during 1. course chemotherapy
Periodo de tiempo: up to 5 days
|
Difference in the Vibrograms from baseline compared to 4 days after initiation of chemotherapy course no. 1.
|
up to 5 days
|
Difference in PRO from baseline to after chemotherapy course no. 3
Periodo de tiempo: through study completion, an average of 1 year and 6 months
|
For patients receiving paclitaxel: Difference in EORTC-QLQ-CIPN20 from baseline compared to after chemotherapy course no. 3.
|
through study completion, an average of 1 year and 6 months
|
Difference in PRO from baseline to after chemotherapy course no. 2
Periodo de tiempo: through study completion, an average of 1 year and 6 months
|
For patients receiving oxaliplatin: Difference in EORTC-QLQ-CIPN20 from baseline compared to after chemotherapy course no. 2. Some patients receiving oxaliplatin will have 6 courses of planned chemotherapy or planned metastatic treatment, in this case comparison will be made after chemotherapy course no. 3.
|
through study completion, an average of 1 year and 6 months
|
Difference in VPT from baseline to af chemotherapy course no. 3
Periodo de tiempo: through study completion, an average of 1 year and 6 months
|
For patients receiving paclitaxel: Difference in the Vibrograms from baseline compared to after chemotherapy course no. 3.
|
through study completion, an average of 1 year and 6 months
|
Difference in VPT from baseline to af chemotherapy course no. 2
Periodo de tiempo: through study completion, an average of 1 year and 6 months
|
For patients receiving oxaliplatin: Difference in the Vibrograms from baseline compared to after chemotherapy course no. 2. Some patients receiving oxaliplatin will have 6 courses of planned chemotherapy or planned metastatic treatment, in this case comparison will be made after chemotherapy course no. 3.
|
through study completion, an average of 1 year and 6 months
|
No. of discontinuations
Periodo de tiempo: through study completion, an average of 1 year and 6 months
|
Number of patients not completing their planned courses of chemotherapy (reasons for discontinuation will be registered).
|
through study completion, an average of 1 year and 6 months
|
No. of dose reductions
Periodo de tiempo: through study completion, an average of 1 year and 6 months
|
Number of patients that need reductions of chemotherapy dose (reasons will be registered)
|
through study completion, an average of 1 year and 6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- REG-088-2019
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .